Tarsus Pharmaceuticals, Inc.
No SEC Form 4 filings for $TARS in the last 30 days.
See all $TARS insider activity →Tarsus Pharmaceuticals (TARS) reported Q2 2026 XDEMVY net product sales of $173.9M, up 69% year over year, and raised full-year 2026 guidance to $685M to $705M. It agreed to acquire Alkeus Pharmaceuticals for $450M upfront and updated R&D guidance to $190M to $210M. Cash was $449.7M at June 30, 2026.
Tarsus will acquire privately held Alkeus Pharmaceuticals for up to $800m to advance gildeuretinol acetate (ALK-001), an investigational once-daily Phase III oral therapy for Stargardt disease. Tarsus will pay $450m upfront ($270m cash, $180m stock) plus up to $350m in milestone payments. Closing is expected later in 2026 pending regulatory approval.
Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
Over the past 7 days, alphai's AI scored 4 news stories mentioning TARS (Tarsus Pharmaceuticals, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent TARS coverage spans mergers & acquisitions, earnings and financial news.
Near-term trading focus is on raised revenue guidance, the $450M Alkeus deal structure, and updated R&D spend that shifts the path to profitability into 2027.
Deal terms and milestone structure create a clear catalyst for TARS risk-reward, tied to regulatory and commercial milestones for gildeuretinol.
The acquisition adds a late-stage asset and creates a near-term catalyst for TARS around deal terms, regulatory path, and milestone probability.
Guidance lift plus a pipeline-expansion acquisition likely supports near-term sentiment, but integration and continued XDEMVY concentration risk remain key swing factors.
The article frames a trade-off: strong XDEMVY revenue momentum and raised guidance versus higher spend, ongoing losses, and reimbursement/regulatory overhang.
alphai scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tarsus Pharmaceuticals (TARS) reported Q2 2026 XDEMVY net product sales of $173.9M, up 69% year over year, and raised full-year 2026 guidance to $685M to $705M. It agreed to acquire Alkeus Pharmaceuticals for $450M upfront and updated R&D guidance to $190M to $210M. Cash was $449.7M at June 30, 2026.
6 min readTarsus will acquire privately held Alkeus Pharmaceuticals for up to $800m to advance gildeuretinol acetate (ALK-001), an investigational once-daily Phase III oral therapy for Stargardt disease. Tarsus will pay $450m upfront ($270m cash, $180m stock) plus up to $350m in milestone payments. Closing is expected later in 2026 pending regulatory approval.
5 min readMacquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.
6 min readTarsus Pharmaceuticals (TARS) reported Q2 revenue of $173.91M and a net loss of $18.55M. The company raised 2026 XDEMVY net product sales guidance to $685M to $705M, citing strong uptake with 700,000+ patients treated. Tarsus also agreed to acquire Alkeus Pharmaceuticals to expand its ophthalmology pipeline.
4 min readTarsus Pharmaceuticals shares fell 0.8% to $64.79 after Q2 results. The company reported Q2 net product sales of $173.9m from XDEMVY, with a $18.6m net loss. Over the past year revenue was $606.3m, and management raised 2026 XDEMVY sales guidance to $685m-$705m. Cash and securities totaled $449.7m.
6 min readTarsus Pharmaceuticals (NASDAQ:TARS) reported Q2 call updates on XDEMVY adoption, saying daily prescribing by eye-care professionals doubled over the past year and retreatment rates are in the high teens, with stabilization near 20%. It also discussed ALK-001 for Stargardt disease, including Phase III NORTHSTAR enrollment and Phase II lesion reduction of ~29% vs placebo. Tarsus agreed to pay $450M upfront for Alkeus plus up to $350M milestones, and raised 2026 R&D guidance to $190M-$210M.
6 min readBiotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.
7 min readTarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for about $450 million, consisting of $270 million cash and $180 million in Tarsus common stock priced at $61.38 per share. Alkeus holders may receive up to $350 million in milestones and tiered royalties on gildeuretinol. Deal approval is in place, with expected close in 2026.
5 min readTarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals in a deal worth up to $800m, including about $450m upfront (around $270m cash and $180m in Tarsus stock) plus up to $350m in milestones. The focus is Alkeus’ Phase III gildeuretinol for Stargardt disease, with topline data expected in 2H 2029.
6 min readTarsus Pharmaceuticals plans to acquire Alkeus Pharmaceuticals and its late-stage Stargardt therapy. The boards and Alkeus stockholders approved. Consideration totals about $450 million, including $270 million cash and $180 million in Tarsus shares at $61.38 per share. Deal expected to close in 2026, subject to conditions, with up to $350 million in milestones and royalties.
7 min read
